Skip to main content
medichelpline
Back to Clinical Feed
Try:
Front ImmunolInfectious Disease

Clinical characteristics, treatment, and outcomes of Oxaliplatin-induced immune thrombocytopenia

14 May 20264 min read0 viewsJournal Feed

GIST

BackgroundAlthough myelosuppression is its common dose-limiting toxicity, oxaliplatin-induced immune thrombocytopenia (OITP), a rare and potentially fatal type II hypersensitivity reaction, is often misdiagnosed as ordinary myelosuppression due to insufficient clinical awareness.MethodsRelevant literature published up to December 31, 2025 were retrieved from databases including PubMed, Scopus, Embase, Web of Science, Cochrane Library, Wanfang Medical Database and China National Knowledge Infrastructure (CNKI). Cases confirmed as OITP were strictly screened for retrospective analysis.ResultsAmong the 40 included patients, the median age was 59 years (range, 36–83 years), with a significant female predominance (65.0%).

The main primary disease was colorectal cancer (92.5%), and the most commonly used chemotherapy regimen was FOLFOX (77.5%). OITP onset was characterized by a distinct latent period, with a median time to onset of the 9th chemotherapy cycle (range, 2–28 cycles).

The clinical manifestations were severe: 82.5% of patients had a platelet count drop to < 25×109/L, with a median nadir of only 6×109/L. Bleeding symptoms were evident in 65.0% of patients, and 52.5% of patients had accompanying systemic hypersensitivity symptoms such as fever and chills.

Clinical Editorial

Summary

Frontiers in Immunology published a clinical update in Infectious Disease on 14 May 2026.

The item focuses on Clinical characteristics, treatment, and outcomes of Oxaliplatin-induced immune thrombocytopenia.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.